TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04912427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab is supplied by Sanofi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is commercially available.
Study: NCT04913467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Groningen Anti-Inflammatory Diet (GrAID)
Description: Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ColoVit capsule
Description: Vitamin B2/B3/C supplement in a ColoPulse-coated capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ColoPulse-placebo capsule
Description: A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
Study: NCT06246695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Oral Jaktinib 100 mg for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Oral Jaktinib 100 mg for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: Oral Itraconazole 200 mg for 9 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin Capsules
Description: Oral Rifampicin 600 mg for 11 day
Study: NCT05679089

Intervention type: DEVICE
Intervention: early detection test
Description: Blood collection and early detection testing

Intervention type: DEVICE
Intervention: early detection test
Description: Blood collection and early detection testing

Intervention type: DEVICE
Intervention: early detection test
Description: Blood collection and early detection testing
Study: NCT05223075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine local anethesia with vasoconstrictor
Description: buccal infiltration only of articaine local anethesia during extraction of lower anterior teeth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine local anethesia with vasoconstrictor
Description: buccal infiltration only of lidocaine local anethesia during extraction of lower anterior teeth
Study: NCT06052709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational balance assessment
Description: There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Occupational balance assessment
Description: There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.
Study: NCT06106139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strict ketogenic diet group
Description: the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclic ketogenic diet group
Description: the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Autonomous ketogenesis group
Description: Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600\~2400 kcal.
Study: NCT04672408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: His bundle pacing
Description: Pacing with capture of the His bundle

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Right ventricular pacing
Description: Pacing from the right ventricular lead (septal or apical)
Study: NCT04124380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure
Description: Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training
Description: Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training
Description: Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training
Description: Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Telehealth
Description: The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
Study: NCT05382546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
Study: NCT05827692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group A
Description: The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group A
Description: The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
Study: NCT05869669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neflamapimod
Description: Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a capsule that looks just like neflamapimod but without the active ingredients
Study: NCT05748574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sleep Well Sachet
Description: Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
Study: NCT05880108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-weeks of Weight Loss
Description: Participants will be asked to participate in a 1x/week center-based nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-weeks of Weight Stability
Description: Participants will be asked to participate in a 1x/week center-based health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for 12 weeks.
Study: NCT05202054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness stress reduction program
Description: Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
Study: NCT04478136

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test of factor levels
Description: Blood draw from central line to check coagulation factors
Study: NCT06450847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soleus Muscle Push Up Exercise
Description: Members will be asked to do the SPUs for 270 minutes/day for most days of the week (minimum 5 days) for 3 months:~1. Begin seated on a bench or chair so knees form a 90-degree angle with feet flat on the floor and toes pointed forward. Keep spine straight and shoulders back (not hunched or rounded forward).~2. Using a slow and controlled tempo, push toes into the floor and lift heels off the ground.~3. Hold for one to two seconds, pushing down on the balls of feet. Keep your thigh muscles relaxed.~4. Slowly lower heels and return to start. That's 1 rep. Without shoes Educational session will be given before the intervention time WhatsApp messages will be sent 1-2 times/day to remind the participants to continue doing the exercise and ascertain compliance. Also, the participants are required to daily fill logbook about the duration (in minutes) of the SPU that they did.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other Exercise
Description: Participants will be asked to continue their regular lifestyle
Study: NCT06269094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: CGM use for 6 weeks during virtual focus groups
Study: NCT06322238

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: PGx panel test
Description: In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mankato), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PGx panel test
Description: In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mankato), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.
Study: NCT06697782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron 8mg
Description: Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant 125 mg
Description: Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
Study: NCT06712355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Concentrate for solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Solution for infusion
Study: NCT06702449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine low dose formulation 1
Description: Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine low dose formulation 2
Description: Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine medium dose formulation 1
Description: Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine medium dose formulation 2
Description: Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine high dose formulation 1
Description: Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine high dose formulation 2
Description: Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Study: NCT05587894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 5 days
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 5 days
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 10 days
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 10 days
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veklury
Description: Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veklury
Description: Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Study: NCT06257056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Laboratories Infinity™ implantable deep brain stimulation system
Description: Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Laboratories Infinity™ implantable deep brain stimulation system
Description: Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
Study: NCT05701540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tegoprazan 50mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 20mg tablet~1. For patients with ERD: two Esomeprazole 20mg tablets~2. For patients with NERD: one Esomeprazole 20mg tablet
Study: NCT05018702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: 1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Study: NCT06314217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everads Injector
Description: Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector
Study: NCT05492149

Intervention type: OTHER
Intervention: Performance follow-up
Description: Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
Study: NCT05352932

Intervention type: DIAGNOSTIC_TEST
Intervention: pancreatic duct biopsy
Description: Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination.
Study: NCT06702449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine HTD formulation 2
Description: Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Study: NCT06453395

Intervention type: OTHER
Intervention: Patients were grouped according to tumor location
Description: Patients were grouped according to tumor location

Intervention type: OTHER
Intervention: Patients were grouped according to tumor location
Description: Patients were grouped according to tumor location

Intervention type: OTHER
Intervention: Patients were grouped according to tumor location
Description: Patients were grouped according to tumor location
Study: NCT06702449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Study: NCT06719674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Professional mechanical plaque removal and Laser
Description: A diode laser will be used as an adjunct to mechanical plaque removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Professional mechanical plaque removal
Description: The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology (13). At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.